Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

Date : 05/07/2019 @ 9:36PM
Source : Edgar (US Regulatory)
Stock : Acura Pharmaceuticals, Inc. (QB) (ACUR)
Quote : 0.201  0.0 (0.00%) @ 1:00PM

Notification That Quarterly Report Will Be Submitted Late (nt 10-q)

 

 

 

    OMB APPROVAL
  UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
OMB Number: 3235-0058
  Expires: February 28, 2022
  Estimated average burden hours per response. 2.50

 

 

  FORM 12b-25 SEC FILE NUMBER
     1-10113
     
    CUSIP NUMBER
  NOTIFICATION OF LATE FILING   00509L 802

 

 

(Check one): ¨  Form 10-K          ¨  Form 20-F            ¨  Form 11-K     [✓] Form 10-Q            ¨  Form 10-D
¨  Form N-SAR      ¨  Form N-CSR

 

For Period Ended:   March 31, 2019

 

¨  Transition Report on Form 10-K
¨  Transition Report on Form 20-F
¨  Transition Report on Form 11-K
¨  Transition Report on Form 10-Q
¨  Transition Report on Form N-SAR

 

For the Transition Period Ended: ____________________

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

 

PART I — REGISTRANT INFORMATION

 

 
 Acura Pharmaceuticals, Inc.
Full Name of Registrant
 
 N/A
Former Name if Applicable
 
616 N. North Court
Address of Principal Executive Office (Street and Number)
 
Palatine, IL 60067
City, State and Zip Code

 

 

 

 

 

  

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

  [√]   (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D,or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

  

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

 The Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2019 could not be filed within the prescribed time period due to difficulties finalizing the materials required to begin the Registrant’s year-end audit of its 2018 financial results as well as to begin the review of the Registrants quarterly review of its 1 st quarter 2019 financial results, as we are seeking to secure additional sources of financing to fund continued operations beyond late May 2019.

 

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification
 
   Peter A. Clemens   847   705-7709
  (Name)   (Area Code)   (Telephone Number)
 
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
 
  Yes   ¨      NO  [√]
 
   The Registrant’s Annual Report on Form 10-K for the annual period ending December 31, 2018 has not been filed.
 
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
 
  Yes   ¨      NO  [√]
 
  If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

 Acura Pharmaceuticals, Inc. 

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:   May 7, 2019   By: /s/ Peter A. Clemens, Senior VP & CFO

 

 

Acura Pharmaceuticals, Inc. (USOTC:ACUR)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more Acura Pharmaceuticals, Inc. Charts.

Acura Pharmaceuticals, Inc. (USOTC:ACUR)
Intraday Stock Chart

Today : Tuesday 16 July 2019

Click Here for more Acura Pharmaceuticals, Inc. Charts.

Latest ACUR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.